DXCM - DexCom, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
125.17
-1.90 (-1.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close127.07
Open127.53
Bid0.00 x 900
Ask0.00 x 800
Day's Range123.79 - 128.00
52 Week Range43.74 - 148.56
Volume660,291
Avg. Volume1,148,932
Market Cap11.059B
Beta (3Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-0.06
Earnings DateNov 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est142.75
Trade prices are not sourced from all markets
  • Could JNJ’s Medical Device Business Report Strong Growth in Q3?
    Market Realist4 days ago

    Could JNJ’s Medical Device Business Report Strong Growth in Q3?

    Johnson & Johnson’s (JNJ) Medical Device business has posted steadily improving performance in recent quarters. Since then, Johnson & Johnson has efficiently implemented a restructuring plan for its Medical Device business, which resulted in significant growth in the segment’s performance. In the second quarter, Johnson & Johnson’s Medical Device business reported sales of ~$7.0 billion, which contributed 33.5% to the company’s total sales of $20.8 billion.

  • PR Newswire5 days ago

    Dexcom Announces Release of Clarity Mobile App

    EDINBURGH , October 11, 2018 /PRNewswire/ -- Mobile app allows patients to quickly access glucose data on their phone for diabetes management   Dexcom , Inc. (NASDAQ:DXCM), a leader in continuous glucose ...

  • The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

    The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    Dexcom Inc NASDAQ/NGS:DXCM

  • Wearable Medical Device Boom Puts These 3 Stocks in Focus
    Zacks8 days ago

    Wearable Medical Device Boom Puts These 3 Stocks in Focus

    Americans depend on wearable medical devices for fitness tracking, blood pressure maintenance, self-glucose monitoring and more. Here, we discuss major companies that are raking in huge profits.

  • Business Wire8 days ago

    DexCom Schedules Third Quarter 2018 Earnings Release and Conference Call for November 6, 2018 at 4:30 p.m. Eastern Time.

    DexCom, Inc. today announced that it plans to release its third quarter 2018 financial results after market close on Tuesday, November 6, 2018. Management will hold a conference call to review the company's third quarter 2018 performance starting at 4:30 p.m.

  • US Diabetes Market Gaining Momentum: 3 Stocks in Focus
    Zacks12 days ago

    US Diabetes Market Gaining Momentum: 3 Stocks in Focus

    A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.

  • Investing in Diabetes Stocks: A Beginner's Guide
    Motley Fool19 days ago

    Investing in Diabetes Stocks: A Beginner's Guide

    Want to put money to work in this $825 billion market? Here's what you need to know.

  • DexCom Inc (NASDAQ:DXCM): Are Analysts Optimistic?
    Simply Wall St.27 days ago

    DexCom Inc (NASDAQ:DXCM): Are Analysts Optimistic?

    DexCom Inc’s (NASDAQ:DXCM): DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The US$12.64bRead More...

  • 10 Boring Stocks Growing Like Weeds
    InvestorPlacelast month

    10 Boring Stocks Growing Like Weeds

    Most investors love a good story — or should I say, a sexy story. In looking for stocks to buy, they like the stories of the companies that are transforming an entire industry or are exploiting a niche that no one even knew existed 20 minutes ago. It’s the rags-to-riches tale, the ground-floor-stock temptation.

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Dexcom Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 10. Index (PMI) data, output in the Healthcare sector is rising.

  • DexCom Has Reported 150% Growth in 2018 Year-to-Date
    Market Realistlast month

    DexCom Has Reported 150% Growth in 2018 Year-to-Date

    The stock of DexCom (DXCM), the leading pure-play diabetes medtech player, has risen ~150%, from $57.99 on January 2, 2018, to $143.48 on September 7, 2018. In the second quarter, it reported revenues of $242.5 million, a YoY (year-over-year) rise of 42.1%. It reported a 35% YoY rise in revenues for the US market, while sales outside the United States rose 78% YoY in Q2 2018.

  • Why DexCom Soared 51.8% in August
    Motley Foollast month

    Why DexCom Soared 51.8% in August

    Growing demand in the wake of next-generation diabetes devices sparked optimism.

  • Here's Why You Should Hold On to DexCom (DXCM) Stock Now
    Zacks2 months ago

    Here's Why You Should Hold On to DexCom (DXCM) Stock Now

    DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...

  • Business Wire2 months ago

    Dexcom Acquires TypeZero Technologies

    DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today that it has acquired TypeZero Technologies, Inc. (“TypeZero”). TypeZero’s offering includes the inControl diabetes management system, designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin delivery. Dexcom, TypeZero and the University of Virginia have had a longstanding, productive relationship in developing important technologies for diabetes management, including inControl for integration with both automated insulin delivery (“AID”) and smart pens.

  • Business Wire2 months ago

    DexCom Announces Upcoming Conference Presentation

    DexCom, Inc. today announced that management will present an update on DexCom at the following upcoming investor conference:

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DXCM earnings conference call or presentation 1-Aug-18 8:30pm GMT

    Q2 2018 DexCom Inc Earnings Call

  • Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring
    Bloomberg2 months ago

    Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring

    Diabetes treatment has evolved since Mary Fortune was diagnosed in 1967 and hospitalized because there was no reliable way monitor her blood sugar. Fortune and other diabetics are benefiting from an explosion in technology and innovation, from under-the-skin sensors that eliminate the need for painful finger pricks, to smartphone alerts when glucose levels rise too high. For glucose monitors alone, the number of published patent applications has grown steadily for a decade and has accelerated significantly since 2015, according to an analysis by the research firm Patinformatics.

  • What Does Tandem Diabetes Care’s Valuation Trend Indicate?
    Market Realist2 months ago

    What Does Tandem Diabetes Care’s Valuation Trend Indicate?

    From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.

  • 3 Stocks That Soared 20% or More This Week -- Which Are Still Buys?
    Motley Fool2 months ago

    3 Stocks That Soared 20% or More This Week -- Which Are Still Buys?

    Can the sizzling momentum continue for these hot stocks?

  • DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
    Zacks2 months ago

    DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View

    Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.

  • Tandem Diabetes Care: Stock Still Soaring after Q2 2018 Results
    Market Realist2 months ago

    Tandem Diabetes Care: Stock Still Soaring after Q2 2018 Results

    The company released its second-quarter financial results on July 30, and the next day, the stock rose 10.95% to $27.56 from its prior day’s close of $24.84. In the second quarter of 2018, Tandem Diabetes Care’s net revenues grew 60% to $34.1 million compared to $21.3 million in the second quarter of 2017. Tandem Diabetes Care anticipates net revenues in fiscal 2018 to be $140 million–$148 million, which reflects 30%–38% year-over-year growth.